Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Import-For-Export Is Among Issues Holding Up Bioterrorism/PDUFA Bill

Executive Summary

Rx import controls are among the remaining issues that need to be reconciled in the bioterrorism/Prescription Drug User Fee Act conference legislation to complete a consensus bill by Memorial Day

You may also be interested in...



Bioterrorism Antitrust Relief Is One Of Last Major Obstacles To Consensus Bill

Antitrust exemptions for pharmaceutical companies who produce bioterrorism countermeasures is one of the last significant obstacles to moving an anti-bioterrorism authorization bill this year

FDA Developing Proposed Rule For Export Of Investigational New Drugs

FDA is developing a proposed rule to address the export of drugs and biologics for investigational use

Rx Import Controls Included In Tauzin/Dingell Bioterrorism Bill

The House Energy & Commerce Committee bioterrorism bill would increase controls on the importation of pharmaceuticals

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel